Matches in SemOpenAlex for { <https://semopenalex.org/work/W2134010988> ?p ?o ?g. }
Showing items 1 to 99 of
99
with 100 items per page.
- W2134010988 endingPage "13" @default.
- W2134010988 startingPage "7" @default.
- W2134010988 abstract "Gemcitabine and paclitaxel are chemotherapeutic agents with clinical antitumor activity in a broad range of malignant solid tumors. Because of preclinical synergy, unique mechanisms of action and resistance, and nonoverlapping toxicities, gemcitabine and paclitaxel combinations are attractive for testing in clinical trials. Prior weekly gemcitabine and paclitaxel regimens administered on a 28-day cycle have been limited by cumulative hematological toxicity on day 15, thus reducing the planned gemcitabine dose intensity. We therefore conducted a phase I trial of a 21-day schedule of weekly gemcitabine and paclitaxel to determine the tolerability, maximum tolerated dose (MTD), and preliminary estimates of efficacy of this regimen.Forty-one patients with advanced malignant solid tumors were accrued. Gemcitabine was given at a fixed dose of 1000 mg/m2 while paclitaxel was administered at an initial dose of 60 mg/m2, then escalated by 15 mg/m2 increments over seven dose levels to a prospectively planned maximum dose of 150 mg/m2. Both agents were infused intravenously on days one and eight every 21 days. At least three patients were enrolled per dose level. No intrapatient dose escalation was allowed.All patients were assessable for toxicity and 31 were assessable for response. The regimen was generally well-tolerated. Dose-limiting thrombocytopenia was observed in one patient at a paclitaxel dose of 135 mg/m2/week (dose level 6). After expansion of this dose level by 14 additional patients, no further dose-limiting toxicities were observed although one patient at dose level seven died of neutropenic sepsis after completing three cycles. There were eight partial responders for an overall response proportion of 26% (95% CI: 11, 41). Twelve patients (39%) had stable disease.This 21-day schedule of gemcitabine and paclitaxel is safe, well-tolerated, and active. The recommended phase II dose is gemcitabine 1000 mg/m2 and paclitaxel 150 mg/m2 on days one and eight every 21 days. The antitumor activity observed with this regimen warrants further investigation." @default.
- W2134010988 created "2016-06-24" @default.
- W2134010988 creator A5022600472 @default.
- W2134010988 creator A5036091074 @default.
- W2134010988 creator A5046084163 @default.
- W2134010988 creator A5053228135 @default.
- W2134010988 creator A5059833300 @default.
- W2134010988 creator A5063441489 @default.
- W2134010988 creator A5070878175 @default.
- W2134010988 creator A5075799959 @default.
- W2134010988 creator A5088861982 @default.
- W2134010988 date "2003-01-01" @default.
- W2134010988 modified "2023-09-26" @default.
- W2134010988 title "Phase I Trial of Gemcitabine and Paclitaxel in Advanced Solid Tumors" @default.
- W2134010988 cites W1898871412 @default.
- W2134010988 cites W1980467576 @default.
- W2134010988 cites W1999879350 @default.
- W2134010988 cites W2020473190 @default.
- W2134010988 cites W2063798212 @default.
- W2134010988 cites W2131524935 @default.
- W2134010988 cites W2135791859 @default.
- W2134010988 cites W2146014573 @default.
- W2134010988 cites W2151116649 @default.
- W2134010988 cites W2161731922 @default.
- W2134010988 cites W2270490184 @default.
- W2134010988 cites W2334640268 @default.
- W2134010988 cites W4255762755 @default.
- W2134010988 doi "https://doi.org/10.1081/cnv-120016398" @default.
- W2134010988 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12643004" @default.
- W2134010988 hasPublicationYear "2003" @default.
- W2134010988 type Work @default.
- W2134010988 sameAs 2134010988 @default.
- W2134010988 citedByCount "6" @default.
- W2134010988 countsByYear W21340109882015 @default.
- W2134010988 countsByYear W21340109882020 @default.
- W2134010988 crossrefType "journal-article" @default.
- W2134010988 hasAuthorship W2134010988A5022600472 @default.
- W2134010988 hasAuthorship W2134010988A5036091074 @default.
- W2134010988 hasAuthorship W2134010988A5046084163 @default.
- W2134010988 hasAuthorship W2134010988A5053228135 @default.
- W2134010988 hasAuthorship W2134010988A5059833300 @default.
- W2134010988 hasAuthorship W2134010988A5063441489 @default.
- W2134010988 hasAuthorship W2134010988A5070878175 @default.
- W2134010988 hasAuthorship W2134010988A5075799959 @default.
- W2134010988 hasAuthorship W2134010988A5088861982 @default.
- W2134010988 hasConcept C126322002 @default.
- W2134010988 hasConcept C143998085 @default.
- W2134010988 hasConcept C197934379 @default.
- W2134010988 hasConcept C2776694085 @default.
- W2134010988 hasConcept C2777063308 @default.
- W2134010988 hasConcept C2777292972 @default.
- W2134010988 hasConcept C2777334693 @default.
- W2134010988 hasConcept C2778375690 @default.
- W2134010988 hasConcept C2779984678 @default.
- W2134010988 hasConcept C2780258809 @default.
- W2134010988 hasConcept C2781413609 @default.
- W2134010988 hasConcept C29730261 @default.
- W2134010988 hasConcept C31760486 @default.
- W2134010988 hasConcept C535046627 @default.
- W2134010988 hasConcept C71924100 @default.
- W2134010988 hasConcept C98274493 @default.
- W2134010988 hasConceptScore W2134010988C126322002 @default.
- W2134010988 hasConceptScore W2134010988C143998085 @default.
- W2134010988 hasConceptScore W2134010988C197934379 @default.
- W2134010988 hasConceptScore W2134010988C2776694085 @default.
- W2134010988 hasConceptScore W2134010988C2777063308 @default.
- W2134010988 hasConceptScore W2134010988C2777292972 @default.
- W2134010988 hasConceptScore W2134010988C2777334693 @default.
- W2134010988 hasConceptScore W2134010988C2778375690 @default.
- W2134010988 hasConceptScore W2134010988C2779984678 @default.
- W2134010988 hasConceptScore W2134010988C2780258809 @default.
- W2134010988 hasConceptScore W2134010988C2781413609 @default.
- W2134010988 hasConceptScore W2134010988C29730261 @default.
- W2134010988 hasConceptScore W2134010988C31760486 @default.
- W2134010988 hasConceptScore W2134010988C535046627 @default.
- W2134010988 hasConceptScore W2134010988C71924100 @default.
- W2134010988 hasConceptScore W2134010988C98274493 @default.
- W2134010988 hasIssue "1" @default.
- W2134010988 hasLocation W21340109881 @default.
- W2134010988 hasLocation W21340109882 @default.
- W2134010988 hasOpenAccess W2134010988 @default.
- W2134010988 hasPrimaryLocation W21340109881 @default.
- W2134010988 hasRelatedWork W1993844652 @default.
- W2134010988 hasRelatedWork W2012690423 @default.
- W2134010988 hasRelatedWork W2088101355 @default.
- W2134010988 hasRelatedWork W2100029565 @default.
- W2134010988 hasRelatedWork W2131794718 @default.
- W2134010988 hasRelatedWork W2151116649 @default.
- W2134010988 hasRelatedWork W2160354293 @default.
- W2134010988 hasRelatedWork W2167562354 @default.
- W2134010988 hasRelatedWork W2170588003 @default.
- W2134010988 hasRelatedWork W2994319618 @default.
- W2134010988 hasVolume "21" @default.
- W2134010988 isParatext "false" @default.
- W2134010988 isRetracted "false" @default.
- W2134010988 magId "2134010988" @default.
- W2134010988 workType "article" @default.